Best Practice & Research Clinical Rheumatology
Volume 20, Issue 4 , Pages 685-694 , August 2006

Systemic lupus erythematosus and pregnancy

  • Munther A. Khamashta, MD, FRCP, PhD (Consultant Physician)

      Affiliations

    • Corresponding Author InformationTel.: +44 20 718 83571; Fax: +44 20 7620 2567.

References 

  1. Gordon PA, Beedham T, Khamashta MA, et al. Systemic lupus erythematosus in pregnancy. The Obstetrician and Gynaecologist. 2004;6:80–87
  2. Boumpas DT, Austin HA, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Annals of Internal Medicine. 1993;119:366–369
  3. Guballa N, Sammaritano L, Schwartzman S, et al. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis and Rheumatism. 2000;43:550–556
  4. Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Seminars in Arthritis and Rheumatism. 2005;35:112–121
  5. Buchanan NM, Toubi E, Khamashta MA, et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Annals of the Rheumatic Diseases. 1996;55:486–488
  6. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis and Rheumatism. 2003;48:3207–3211
  7. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10:401–404
  8. Buyon JP, Kalunian KC, Ramsey-Goldman R, et al. Assessing disease activity in SLE patients during pregnancy. Lupus. 1999;8:677–684
  9. Khamashta MA, Ruiz-Irastorza G, Hughes GRV. Systemic lupus erythematosus flares during pregnancy. Rheumatic Diseases Clinics of North America. 1997;23:15–30
  10. Ruiz-Irastorza G, Khamashta MA, Gordon C, et al. Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale. Arthritis and Rheumatism (Arthritis Care and Research). 2004;51:78–82
  11. Petri M. Hopkins Lupus Pregnancy Center: 1987 to 1996. Rheumatic Diseases Clinics of North America. 1997;23:1–13
  12. Rahman P, Gladman DD, Urowitz MB. Clinical predictors of fetal outcome in systemic lupus erythematosus. The Journal of Rheumatology. 1998;25:1526–1530
  13. Petri M. Pregnancy in SLE. Baillière's Clinical Rheumatology. 1998;12:449–476
  14. Moroni G, Ponticelli C. The risk of pregnancy in patients with lupus nephritis. Journal of Nephrology. 2003;16:161–167
  15. Carmona F, Font J, Moga I, et al. Class III-IV proliferative lupus nephritis and pregnancy: a study of 42 cases. American Journal of Reproductive Immunology. 2005;53:182–188
  16. Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus. 2006;15:148–155
  17. Oviasu E, Hicks J, Cameron JS. The outcome of pregnancy in women with lupus nephritis. Lupus. 1991;1:19–25
  18. Lima F, Buchanan NM, Khamashta MA, et al. Obstetric outcome in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. 1995;25:184–192
  19. Burkett G. Lupus nephropathy and pregnancy. Clin Obstet Gynecol. 1985;28:310–323
  20. Chen HH, Lin HC, Yeh JC, et al. Renal biopsy in pregnancies complicated by undetermined renal disease. Acta Obstetricia et Gynecologica Scandinavica. 2001;80:888–893
  21. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis. 2006;4:295–306
  22. Gomez-Puerta JA, Martin H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?. Medicine (Baltimore). 2005;84:225–230
  23. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management and controversies. Obstetrics and Gynecology. 2003;101:1333–1344
  24. Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clinical and Experimental Rheumatology. 1996;14:131–136
  25. Stone S, Pijnenborg R, Vercruysse L, et al. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta. 2006;27:457–467
  26. Derksen RH, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis and Rheumatism. 2004;50:1028–1039
  27. Stone S, Hunt BJ, Khamashta MA, et al. Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol. Journal of Thrombosis and Haemostasis. 2005;3:243–245
  28. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American Journal of Obstetrics and Gynecology. 1996;174:1584–1589
  29. Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314:253–257
  30. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomised, controlled trial of treatment. Obstetrics and Gynecology. 2002;100:408–413
  31. Pattison NS, Chamley LW, Birdsall M, et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomised controlled trial. American Journal of Obstetrics and Gynecology. 2000;183:1008–1012
  32. Clark AL, Branch DW, Silver RM, et al. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy. Obstetrics and Gynecology. 1999;93:437–441
  33. Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. American Journal of Obstetrics and Gynecology. 2000;182:122–127
  34. Hunt BJ, Gattens M, Khamashta M, et al. Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagulation & Fibrinolysis. 2003;14:735–739
  35. Ruiz-Irastorza G, Khamashta MA. Management of thrombosis in antiphospholipid syndrome and systemic lupus erythematosus in pregnancy. Annals of the New York Academy of Sciences. 2005;1051:606–612
  36. Brucato A, Frassi M, Franceschini F, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis and Rheumatism. 2001;44:1832–1835
  37. Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. Journal of the American College of Cardiology. 1998;31:1658–1666
  38. Gordon P, Khamashta MA, Rosenthal E, et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. The Journal of Rheumatology. 2004;31:2480–2487
  39. Saleeb S, Copel J, Friedman D, et al. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis and Rheumatism. 1999;42:2335–2345
  40. Hughes G. The eradication of congenital heart block. Lupus. 2004;13:489
  41. Neiman AR, Lee LA, Weston WL, et al. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. The Journal of Pediatrics. 2000;137:674–680

PII: S1521-6942(06)00044-1

doi: 10.1016/j.berh.2006.04.003

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 4 , Pages 685-694 , August 2006

Article Tools